C Hanusch
Overview
Explore the profile of C Hanusch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, et al.
ESMO Open
. 2024 Apr;
9(5):103009.
PMID: 38663168
Background: The GENEVIEVE study, comparing neoadjuvant cabazitaxel versus paclitaxel in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC), previously reported significant differences...
2.
Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J, et al.
Ann Oncol
. 2022 Aug;
33(11):1149-1158.
PMID: 35961599
Background: Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo...
3.
Loibl S, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, et al.
Ann Oncol
. 2022 May;
33(7):743-744.
PMID: 35595658
No abstract available.
4.
Helbrich H, Braun M, Hanusch C, Mueller G, Falk H, Flondor R, et al.
Breast Cancer Res Treat
. 2021 Mar;
188(2):351-359.
PMID: 33788134
Purpose: This study examines congruence between self-reported and device-measured physical activity data in women with early breast cancer and compares trajectories under different treatments. Methods: Women with non-metastatic breast cancer...
5.
Fasching P, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al.
Ann Oncol
. 2020 Oct;
32(1):49-57.
PMID: 33098995
Background: The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2...
6.
Karn T, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, et al.
Ann Oncol
. 2020 May;
31(9):1216-1222.
PMID: 32461104
Background: The predictive value of tumor mutational burden (TMB), alone or in combination with an immune gene expression profile (GEP), for response to neoadjuvant therapy in early triple negative breast...
7.
Loibl S, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, et al.
Ann Oncol
. 2019 May;
30(8):1279-1288.
PMID: 31095287
Background: Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy...
8.
Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, et al.
Ann Oncol
. 2016 Nov;
28(3):497-504.
PMID: 27831502
Background: The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen...
9.
von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, et al.
Eur J Cancer
. 2016 Jun;
64:12-21.
PMID: 27323347
Background: Patients with invasive residual disease after neoadjuvant chemotherapy (NACT) are considered to have chemo-resistant breast cancer. Bisphosphonates are an established treatment for bone metastases and are of potential benefit...
10.
Loibl S, Untch M, Fasching P, Eggemann H, Jackisch C, Blohmer J, et al.
Ann Oncol
. 2014 Sep;
25(12):2363-2372.
PMID: 25223482
Background: The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer...